Loading
HEM파마 Stock: price and insider trades · South Korea
HEM파마: what insiders have been doing
We have very little insider data for HEM파마 so far. With so few records, no pattern can be drawn yet. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Insider Decl.
n/a
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 23,592 of 24,158 companies
10.9
score / 100
Value19
Quality3
FCF yld-6.4%
Earn yld-8.3%
EV/EBITDA·
ROE-194%
Gross mgn4.9%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
₩39,900
Analyst consensus
Income statement
Revenue₩13B
Gross profit₩631.5M5% margin
EBITDA-₩20.5B-158% margin
Net income-₩23.8B-177.7% margin
Balance sheet & cash
Market cap₩286.3B
Total debt₩19.3B
Free Cash Flow-₩18.3B
Debt / Equity1121%
Profitability & ownership
ROE-194.4%
ROA-23.8%
% insiders25.2%
% institutions0.4%
Declarations0 total
No declarations found
0 of 0 declarations
About HEM파마
HEM파마 is a company in the health and pharmaceutical sector, listed on the XKRX market. It specializes in the development and marketing of pharmaceutical products.
